Walmart has reached a settlement deal for shareholder lawsuits regarding its handling of opioids, as reported by The Independent. The proposed settlement involves three lawsuits filed by shareholders on behalf of the company. According to a regulatory filing, insurance carriers will pay Walmart $123 million, excluding any attorneys’ fees and expenses awarded by the court to the plaintiffs’ counsel. Additionally, Walmart has agreed to uphold specific corporate governance practices for at least five years as part of the settlement terms.
It is important to note that Walmart’s acceptance of the settlement does not equate to an admission of liability. The agreement is still subject to court approval. The lawsuits, filed in the Delaware Court of Chancery, alleged that current and former directors and officers of Walmart breached their fiduciary duties by not effectively monitoring the company’s distribution and dispensing of prescription opioids.
In a separate legal matter in 2022, Walmart had previously agreed to settle nationwide lawsuits by paying $3.1 billion. These lawsuits focused on the impact of prescriptions filled by Walmart pharmacies for potent prescription opioid painkillers.
The settlement deal undertaken by Walmart showcases the ongoing legal repercussions and financial commitments faced by companies involved in the opioid crisis. The intricacies of the settlement agreement illustrate the multifaceted challenges corporations face concerning accountability and oversight in sensitive matters like healthcare and pharmaceutical distribution.